Cargando…

Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial

BACKGROUND: Adenomyosis is a benign uterine disease characterized by invasion of endometrium into the myometrium resulting in heavy menstrual bleeding and pain (dysmenorrhea). Hysterectomy is established as the final treatment option when conservative treatment fails. Uterine artery embolization (UA...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bruijn, Annefleur Machteld, Lohle, Paul NM, Huirne, Judith AF, de Vries, Jolanda, Twisk, Moniek, Hehenkamp, Wouter JK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856934/
https://www.ncbi.nlm.nih.gov/pubmed/29496654
http://dx.doi.org/10.2196/resprot.8512
_version_ 1783307373789577216
author de Bruijn, Annefleur Machteld
Lohle, Paul NM
Huirne, Judith AF
de Vries, Jolanda
Twisk, Moniek
Hehenkamp, Wouter JK
author_facet de Bruijn, Annefleur Machteld
Lohle, Paul NM
Huirne, Judith AF
de Vries, Jolanda
Twisk, Moniek
Hehenkamp, Wouter JK
author_sort de Bruijn, Annefleur Machteld
collection PubMed
description BACKGROUND: Adenomyosis is a benign uterine disease characterized by invasion of endometrium into the myometrium resulting in heavy menstrual bleeding and pain (dysmenorrhea). Hysterectomy is established as the final treatment option when conservative treatment fails. Uterine artery embolization (UAE) in patients with symptomatic adenomyosis has demonstrated to reduce symptoms and improve quality of life. However, randomized controlled trials are lacking. OBJECTIVE: With this study, we aim to evaluate the impact of UAE on Health-Related Quality of Life (HRQOL) in a randomized comparison to hysterectomy in patients with symptomatic adenomyosis. METHODS: This is a multicenter non-blinded randomized controlled trial comparing UAE and hysterectomy. Eligible patients are symptomatic premenopausal women without the desire to conceive and who have symptomatic magnetic resonance imaging (MRI)–confirmed pure adenomyosis or dominant adenomyosis accompanied by fibroids. After obtaining informed consent, patients will be randomly allocated to treatment in a 2:1 UAE versus hysterectomy ratio. The primary objective is HRQOL at 6 months following the assigned intervention. Secondary outcomes are technical results, pain management, clinical outcomes, HRQOL, and cost effectiveness during 2 years of follow-up. In addition, transvaginal ultrasound (TVUS) and MRI will be performed at regular intervals after UAE. RESULTS: Patient enrollment started November 2015. The follow-up period will be completed two years after inclusion of the last patient. At the time of submission of this article, data cleaning and analyses have not yet started. CONCLUSIONS: This trial will provide insight for caretakers and future patients about the effect of UAE compared to the gold standard hysterectomy in the treatment of symptomatic adenomyosis and is therefore expected to improve patients’ wellbeing and quality of life. TRIAL REGISTRATION: Netherlands Trial Register NTR5615; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5615 (Archived by WebCite at http://www.webcitation.org/6xZRyXeIF)
format Online
Article
Text
id pubmed-5856934
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-58569342018-03-26 Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial de Bruijn, Annefleur Machteld Lohle, Paul NM Huirne, Judith AF de Vries, Jolanda Twisk, Moniek Hehenkamp, Wouter JK JMIR Res Protoc Protocol BACKGROUND: Adenomyosis is a benign uterine disease characterized by invasion of endometrium into the myometrium resulting in heavy menstrual bleeding and pain (dysmenorrhea). Hysterectomy is established as the final treatment option when conservative treatment fails. Uterine artery embolization (UAE) in patients with symptomatic adenomyosis has demonstrated to reduce symptoms and improve quality of life. However, randomized controlled trials are lacking. OBJECTIVE: With this study, we aim to evaluate the impact of UAE on Health-Related Quality of Life (HRQOL) in a randomized comparison to hysterectomy in patients with symptomatic adenomyosis. METHODS: This is a multicenter non-blinded randomized controlled trial comparing UAE and hysterectomy. Eligible patients are symptomatic premenopausal women without the desire to conceive and who have symptomatic magnetic resonance imaging (MRI)–confirmed pure adenomyosis or dominant adenomyosis accompanied by fibroids. After obtaining informed consent, patients will be randomly allocated to treatment in a 2:1 UAE versus hysterectomy ratio. The primary objective is HRQOL at 6 months following the assigned intervention. Secondary outcomes are technical results, pain management, clinical outcomes, HRQOL, and cost effectiveness during 2 years of follow-up. In addition, transvaginal ultrasound (TVUS) and MRI will be performed at regular intervals after UAE. RESULTS: Patient enrollment started November 2015. The follow-up period will be completed two years after inclusion of the last patient. At the time of submission of this article, data cleaning and analyses have not yet started. CONCLUSIONS: This trial will provide insight for caretakers and future patients about the effect of UAE compared to the gold standard hysterectomy in the treatment of symptomatic adenomyosis and is therefore expected to improve patients’ wellbeing and quality of life. TRIAL REGISTRATION: Netherlands Trial Register NTR5615; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5615 (Archived by WebCite at http://www.webcitation.org/6xZRyXeIF) JMIR Publications 2018-03-01 /pmc/articles/PMC5856934/ /pubmed/29496654 http://dx.doi.org/10.2196/resprot.8512 Text en ©Annefleur Machteld de Bruijn, Paul NM Lohle, Judith AF Huirne, Jolanda de Vries, Moniek Twisk, QUESTA-Trial Group, Wouter JK Hehenkamp. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 01.03.2018. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
de Bruijn, Annefleur Machteld
Lohle, Paul NM
Huirne, Judith AF
de Vries, Jolanda
Twisk, Moniek
Hehenkamp, Wouter JK
Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial
title Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial
title_full Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial
title_fullStr Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial
title_full_unstemmed Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial
title_short Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial
title_sort uterine artery embolization versus hysterectomy in the treatment of symptomatic adenomyosis: protocol for the randomized questa trial
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856934/
https://www.ncbi.nlm.nih.gov/pubmed/29496654
http://dx.doi.org/10.2196/resprot.8512
work_keys_str_mv AT debruijnannefleurmachteld uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial
AT lohlepaulnm uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial
AT huirnejudithaf uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial
AT devriesjolanda uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial
AT twiskmoniek uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial
AT uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial
AT hehenkampwouterjk uterinearteryembolizationversushysterectomyinthetreatmentofsymptomaticadenomyosisprotocolfortherandomizedquestatrial